Canonical NFκB signaling via p65/RELA is known to promote carcinogenesis, enhance tumor cell survival and tumor progression, promote the development of metastatic disease, and induce resistance to standard of care chemotherapy regimens in TNBC37–42. The gene discussed is NFKB1; the disease is metastatic neoplasm.